Enabling optimal antimicrobial use in East Africa

最近，人们越来越意识到细菌，特别是细菌，对以前杀死它们的药物治疗没有反应，这一现象被称为抗菌素耐药性(AMR)，这是对人类和动物健康的全球威胁。正在探索许多方法来改善这一问题，包括更好地使用抗生素的迫切需要。抗生素的最佳使用必须确保不适于细菌感染的人继续获得他们需要的药物，同时确保细菌没有机会对这些“神奇子弹”产生抗药性。在提高实验室能力方面进行了巨大的投资，这使我们能够检测和描述AMR，并通过监测网络向各国政府和国际机构报告这一问题。在实验室监测方面的这些投资没有得到加强监测或改善抗生素使用(ABU)干预措施的配合，特别是在低收入国家。我们建议将东非全球挑战研究基金(GCRF)在AMR领域的四项投资合并为GCRF集群。我们将共同负责审查和“综合”我们在东非背景下从人类和动物健康角度得出的所有ABU研究成果。我们将共同努力，共同设计“基本信息包”，以优化东非地区的阿布扎比，并确定使用该一揽子计划的干预措施，以改变社区和卫生系统中的阿布扎比行为。

Recently, there has been an increasing awareness of the global threat to human and animal health that is presented by the failure of germs, specifically bacteria, to respond to treatment with medicines which formerly killed them, a phenomenon known as Antimicrobial Resistance (AMR). Many approaches are being explored to ameliorate this problem, including the critical need to make better use of antibiotics. Optimal use of antibiotics must ensure both that people unwell with bacterial infections continue to have access to medicines that they need and bacteria do not have the opportunity to develop resistance to these "magic bullets". Huge investments have been made in improved laboratory capacity, which permits us to detect and describe AMR and report this problem through surveillance networks to governments and international agencies. These investments in laboratory surveillance have not been matched by enhanced surveillance of or interventions to improve antibiotic use (ABU), particularly in low income countries. We propose to bring together four Global Challenges Research Fund (GCRF) investments in the field of AMR in East Africa into a GCRF cluster. We will collectively take responsibility for reviewing and "synthesising" all of our ABU research findings from the East African context from across human and animal health. We will work together to co-design "an essential information package" to optimise ABU in the East African context and to define an intervention using this package to change ABU behaviours in communities and health systems.